Dyne Therapeutics

Public biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo

With a US Food and Drug Administration partial clinical hold lifted, Avidity Biosciences, Inc. is moving forward with a Phase III trial of its antibody-oligonucleotide conjugate (AOC) candidate delp

A team at Atlas Venture began working on how to deliver small interfering RNA (siRNA) to the kidney three years ago and created a platform similar to technologies that have emerged for delivering olig

A recent conference in China spotlighted trends around diversification of bioconjugates, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) seen leading the novel